Rogerio Vivaldi

Dr. Rogerio Vivaldi is the former President, CEO, and Director of Sigilon Therapeutics. His previous executive leadership roles include Executive Vice President and Chief Global Therapeutics Officer at Bioverativ, Executive Vice President and Chief Commercial Officer at Spark Therapeutics, CEO and Director of Minerva Neurosciences, and Senior Vice President at Genzyme, where he led the approval of over 20 orphan products globally as head of the rare disease business.

Currently, Dr. Vivaldi serves on the Board of Directors for Viatris (VTRS) on the Compliance & Risk Oversight and Science & Technology Committees, as a Board Member and Co-Chair of the Programs Committee for Latinos in Bio, and as Executive Chairman of Vesper Bio. He is also the former Director and Chair of the Global Therapeutic Strategy and Access Committee at Crinetics Pharmaceuticals (acquired by Vertex) and the CEO of Vivaldi Rare Consulting LLC.